Lonza and Vineti have entered a partnership in the cell and gene therapy field and across Lonza’s ‘vein-to-vein’ delivery network. Both Lonza and Vineti will become preferred partners, respectively for patient tissue tracking and for contract development and manufacturing services in cell and gene therapy.

The partnership comprises an integrated offering including logistics, scheduling, distribution, Chain of Condition, Chain of Custody, Chain of Identity, and Lonza’s solutions such as MODA-ES™, a next-gen electronic batch record execution solution that offers specific functionalities for cell and gene therapies manufacturing. Lonza and its partners will work to address supply chain hurdles faced by developers of personalized therapeutics – including autologous therapies, matched-allogeneic therapies, and personalized cancer vaccines – as they prepare for the commercial launch of their therapies.

The Vineti supply chain orchestration (SCO) platform serves commercial cell & gene therapy products and will help Lonza’s customers to keep a real-time end-to-end connection between Lonza and the points of care that prescribe their therapies. Together, the Lonza-Vineti solution will seek to provide biopharmaceutical developers with a pre-integrated SCO and manufacturing system that will offer digital, optimized end-to-end traceability and control.

The partnership aims to establish faster, simpler operations and scale for cell and gene therapies, and to reduce the time that biopharmaceutical developers need to spend evaluating, implementing, and validating different systems. The partnership will also be working to provide this system worldwide, using Lonza’s global manufacturing presence and Vineti’s network of medical centers.